Trials / Completed
CompletedNCT06482437
Safety and Efficacy of NMD670 in Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease
A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of NMD670 Over 21 Days in Ambulatory Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 81 (actual)
- Sponsor
- NMD Pharma A/S · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This Phase 2a study aims to evaluate the efficacy, safety and tolerability of NMD670 vs placebo administered twice a day (BID) for 21 days in ambulatory adult patients with Charcot-Marie-Tooth disease type 1 and type 2.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NMD670 | Tablets taken twice daily for 21 days |
| DRUG | Placebo | Tablets taken twice daily for 21 days |
Timeline
- Start date
- 2024-09-30
- Primary completion
- 2025-10-28
- Completion
- 2025-11-04
- First posted
- 2024-07-01
- Last updated
- 2025-11-12
Locations
19 sites across 5 countries: United States, Belgium, Denmark, France, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06482437. Inclusion in this directory is not an endorsement.